Suspended I think its positive, page-15

I see today Unilife (UNS) has just done a deal with Amgen for drug delivery technology.
Couple of observations of interest. Amgen just been paid UNS a $20M licence fee with another $30M paid for a convertible note.
Yet the sp has only risen 6%. What the hell going on there. In contrast OBJ looking to receive $20M in revenue by 2017 to get performance rights over the line.
UNS quite happy to release financial arrangements. OBJ not.